Critical shortage of intravenous aminophylline expected to resolve in late October
Omega Laboratories reports its aminophylline 25 mg/mL intravenous solution (DIN 00582662) remains in a Tier 3 critical shortage after a manufacturing disruption. The shortage began May 4, 2026 and is expected to end Oct 29, 2026; the company notes a Tier 3 substitute product is available.
Aminophylline is used in acute asthma and COPD care — check the substitute product and stock before the shortage ends.
Shortage expected to end: Oct 29, 2026 All deadlines
Ask about this brief
Answers are written by AI from this brief and can be wrong. Check the original source before you act.
2 free questions a day without an account. Members ask as often as they like, free.
Not medical, legal or immigration advice. Questions are kept anonymously to improve our briefs.
Read the original
Official source: Critical shortage of intravenous aminophylline expected to resolve in late October (opens in a new tab) — Health Product Shortages Canada